Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2012

View Archived Issues

Novel RANKL inhibitor reduces bone resorption in vivo

Researchers disclose lixisenatide data from GetGoal and other trials

U.S. researchers present new low-cost metabolic disease model

Lycera generates novel ROR-gamma antagonists

Chinese researchers develop new vaccines

Daiichi Sankyo presents new diacylglycerol O-acyltransferase inhibitors

Bristol-Myers Squibb reports preparation of novel mGlu5 receptor modulators

Gedeon Richter patents novel bradykinin B1 receptor antagonists

Avanir Pharmaceuticals to begin phase II AVP-923 study

Tengion reports continued progress with Neo-Urinary Conduit

Phase I and II trials assess Gradalis cancer vaccines

U.S. study reveals microRNAs with prognostic significance in kidney cancer

Cara Therapeutics reports results from phase II CR-845 trial

Ubidecarenone investigated for oncolytic activity

Ampio Pharmaceuticals schedules pre-IND meeting for Optina

BioSante Pharmaceuticals plans new phase III LibiGel trials

Protalix receives milestone payment for Elelyso approval

DSMB issues recommendation on phase III program for SFP-iron replacement

Astellas and DNDi launch drug discovery collaboration for three neglected tropical diseases

FDA approves companion diagnostics for Genentech anticancer drug

Stiefel acquires worldwide rights to Toctino

GE Healthcare to provide imaging agent to Australian government for Alzheimer's study

Genzyme files applications for approval of Lemtrada

Promising preclinical data reported on BT-2111

New ENTPD5 inhibitors developed by University of Texas System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...